.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Treatment Options in Triple-Class Refractory Multiple Myeloma

EP. 1: Treatment Advances in Triple-Class Refractory/Relapsed Myeloma

January 14th 2021

EP. 2: INN Melphalan Flufenamide in Triple-Class Refractory/Relapsed MM

January 14th 2021

EP. 3: HORIZON vs MAMMOTH Explored in R/R Multiple Myeloma

January 14th 2021

EP. 4: RRMM: INN Melphalan Flufenamide/DEX and Extramedullary Disease

January 14th 2021

EP. 5: RRMM & High-Risk Cytogenetics: INN Melphalan Flufenamide/DEX

January 14th 2021

EP. 6: INN Melphalan Flufenamide–DEX for Older Patients With RRMM

January 14th 2021

EP. 7: RRMM: INN Melphalan Flufenamide After Alkylator Therapy

January 28th 2021

EP. 8: RRMM: Incorporating INN Melphalan Flufenamide Into Clinical Practice

January 28th 2021